Why Some Doctors Are Breaking Rules To Prescribe Peptides
whatshot 6 snips
Feb 25, 2026
A clear tour of how peptides fit into U.S. law and why some providers test legal limits. Definitions and the two regulatory tracks for peptides set the stage. Discussion of compounding pharmacies, unapproved peptide lists, and a high-profile DOJ case. Practical breakdown of who faces liability and why enforcement can be inconsistent.
27:15
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
question_answer ANECDOTE
TaylorMade Compounding Criminal Case
Matt Kaeberlein recounts the TailorMade Compounding prosecution where the CEO was criminally convicted for distributing unapproved peptides.
DOJ cited BPC-157, Cerebrolycin, CJC-1295, Ipamorelin and others as examples leading to criminal charges and FDA safety flags.
insights INSIGHT
Two Regulatory Paths For Peptides
Peptides are regulated by FDA but fall into two frameworks: biologics under the Public Health Services Act or drugs under the Food Drug and Cosmetic Act.
Chemically synthesized peptides (e.g., BPC-157, CJC-1295, ipamorelin) are treated as drugs under the FD&C Act, changing approval and compounding rules.
insights INSIGHT
FDA Approval Is The Legal Line
FDA approval is the core legal threshold: approved peptides can be prescribed (including off-label), unapproved peptides are technically illegal to market or facilitate.
Compounding approved drugs is tightly limited to patient-specific needs or FDA-declared shortages; bulk protocol-driven compounding is illegal though enforcement is inconsistent.
Get the Snipd Podcast app to discover more snips from this episode
Peptides are everywhere in longevity and functional medicine, but what does the law actually say? In this episode, Dr. Matt Kaeberlein breaks down what a peptide is and the complex regulatory landscape governing peptides in the United States, from FDA approval frameworks to the legal gray zones surrounding compounding pharmacies and unapproved substances.Drawing on the Federal Food, Drug, and Cosmetic Act and real-world enforcement cases, this episode offers a clear-eyed, non-judgmental examination of what is legal, what is tolerated, and what carries genuine risk for physicians, pharmacies, and patients alike. An essential listen for anyone navigating the rapidly evolving world of peptide therapeutics.Timestamps:00:00 — The Tailor Made Compounding Case: Criminal Prosecution & FDA-Flagged Peptides00:54 — Welcome & Episode Overview: The Regulatory Environment of Peptides01:36 — What Is a Peptide? Definitions and Biological Context03:26 — Are Peptides Regulated by the FDA?04:16 — Two Regulatory Frameworks: Biologics vs. Chemically Synthesized Drugs05:17 — The Food, Drug, and Cosmetic Act: Which Peptides Fall Under It?06:11 — Why Two Frameworks Exist: A Brief Legislative History07:06 — The Core Rule: FDA Approval vs. Unapproved Status07:54 — FDA-Approved Peptides: What Can Legally Be Prescribed09:11 — Compounding Pharmacies: When Is It Legal?10:01 — The Unapproved Peptide Bucket: A Long List10:55 — Legal Status of Unapproved Peptides Under U.S. Law12:34 — The Bulk Drug Substances List: What It Is and What It Isn't14:11 — FDA's "Significant Safety Risk" Flagged Peptides15:04 — Why Some Pharmacies Still Compound Unapproved Peptides16:44 — The Gray Area: Speeding Analogies and Cultural Norms17:38 — Degrees of Risk: Formulation, Approval Status, and Data Quality18:38 — Who Bears Legal Liability? Pharmacies, Physicians, and Patients19:39 — The Tailor Made Compounding Case: DOJ Action and Criminal Conviction20:34 — Risk to Physicians and Patients Summarized21:24 — Self-Sourcing Peptides Online: What Consumers Should Know22:14 — Prescription Drugs Without a Prescription: Legal Nuance23:06 — Final Thoughts: The State of Peptide Medicine Today23:58 — How Enforcement Norms Can Shift and Why It Matters Now24:48 — Questions to Ask Yourself: Risk Tolerance and Physician Choice25:21 — An Informed Consent Framework for Peptide Use26:03 — Coming Up: Individual Peptide Deep-Dives in Future Episodes
The Optispan Podcast with Matt Kaeberlein